ATLL
MCID: ADL017
MIFTS: 57

Adult T-Cell Leukemia (ATLL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Adult T-Cell Leukemia

MalaCards integrated aliases for Adult T-Cell Leukemia:

Name: Adult T-Cell Leukemia 12 36 15 37
Adult T-Cell Leukemia/lymphoma 12 52 58
Leukemia-Lymphoma, Adult T-Cell 6 43
Atll 52 58
Adult T-Cell Leukaemia/lymphoma 52
T Cell Leukemia Lymphoma Adult 54
Adult T-Cell Lymphoma/leukemia 71
Adult T-Cell Leukaemia 52
Adult T-Cell Lymphoma 52
Leukemia, T-Cell 71

Characteristics:

Orphanet epidemiological data:

58
adult t-cell leukemia/lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare skin diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050523
KEGG 36 H00009
MeSH 43 D015459
NCIt 49 C3184
SNOMED-CT 67 77430005
ICD10 32 C91.5 C91.50
MESH via Orphanet 44 D015459
ICD10 via Orphanet 33 C91.5
UMLS via Orphanet 72 C0023493
Orphanet 58 ORPHA86875
UMLS 71 C0023492 C0023493

Summaries for Adult T-Cell Leukemia

KEGG : 36 Adult T-cell leukemia (ATL) is one of the most aggressive hematologic malignancies and is caused by human T-cell leukemia virus type 1 (HTLV-1). The HTLV-1 Tax protein has been demonstrated to be the oncogenic protein of the virus. Tax may contribute to the process of carcinogenesis by a variety of mechanisms, including upregulating the expression of cellular genes involved in T cell growth and proliferation, including IL-2, IL-2R-alpha, and IL-15. However, ATL cells do not always need Tax expression in the later stage of leukemogenesis. Genetic and epigenetic changes should be implicated in such multistep leukemogenesis. Regarding genetic changes, mutation of p53, and deletion of p16 have been reported in ATL. Mutations of Fas gene are also reported in patients with ATL cells. However, such genetic changes were not frequently detected. In this regard, epigenetic change of p16/INK4A gene was more frequent in ATL cells, and accumulated according to the disease progression. This finding suggests that epigenetic change, including DNA methylation, plays an important role in the leukemogenesis of ATL.

MalaCards based summary : Adult T-Cell Leukemia, also known as adult t-cell leukemia/lymphoma, is related to tropical spastic paraparesis and peripheral t-cell lymphoma. An important gene associated with Adult T-Cell Leukemia is PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and Viral carcinogenesis. The drugs Zidovudine and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and skin, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Disease Ontology : 12 A T-cell leukemia that results in abnormal increase of lymphocytes, derives from T-cells, has material basis in Human T-lymphotropic virus 1, which is transmitted by sexual contact, transmitted by contaminated needles used by intravenous-drug users, and transmitted by breast feeding. The infection results in formation of skin lesions.

NIH Rare Diseases : 52 Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1) . The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy ), increased liver and spleen size (hepatosplenomegaly ), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as "holes" on a standard bone x-ray ), and skin lesions. There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases). The best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. Medication may include CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone ) or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone). In some patients, a bone marrow transplant may be recommended.

Wikipedia : 74 Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare cancer of the immune system's T-cells caused by... more...

Related Diseases for Adult T-Cell Leukemia

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3

Diseases related to Adult T-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 556)
# Related Disease Score Top Affiliating Genes
1 tropical spastic paraparesis 33.3 IL2RA IL2 FOXP3 CNTN2
2 peripheral t-cell lymphoma 31.5 TP53 TNFRSF8 IL2 FOXP3 CCR4
3 lymphoma 31.3 TP53 TNFRSF8 IL2RA IL2 CCR6 BCL2L1
4 lymphocytic leukemia 31.2 TP53 IL2RA IL2 CCR6
5 t-cell adult acute lymphocytic leukemia 31.2 TP53 TNFRSF8 PTHLH IL2RA IL2 FOXP3
6 prolymphocytic leukemia 31.0 TP53 IL2RA CD7
7 marek disease 31.0 TP53 TNFRSF8
8 cutaneous t cell lymphoma 30.9 TNFRSF8 IL2RA IL2 CCR6 CCR4
9 alk-negative anaplastic large cell lymphoma 30.9 PMAIP1 CCR4 BCL2L1
10 t-cell leukemia 30.7 TP53 SPOCK3 PRDM16 PMAIP1 PDLIM2 IL2RA
11 primary cutaneous t-cell lymphoma 30.7 TNFRSF8 IL2RA
12 mycosis fungoides 30.7 TNFRSF8 IL2RA IL2 FOXP3 CD7 CCR6
13 anaplastic large cell lymphoma 30.6 TNFRSF8 IL2RA CD4 CCR4
14 dermatitis 30.5 IL2 FOXP3 CCR6 CCR4
15 lymphopenia 30.5 IL2RA IL2 FOXP3 CCR6 BCL11B
16 lymphoma, hodgkin, classic 30.5 TNFRSF8 IL2RA IL2 CCR6 CCR4 BCL2L1
17 hairy cell leukemia 30.4 TP53 IL2RA IL2
18 acute t cell leukemia 30.4 TP53 CD7 CD4 BCL11B
19 autoimmune disease 30.3 IL2RA IL2 FOXP3 CCR6 CCR4
20 follicular mucinosis 30.3 TNFRSF8 CD7 CD4
21 pancytopenia 30.2 TP53 IL2RA FOXP3 CD7 CD4
22 exanthem 30.2 IL2 CD4 CCR6
23 lymphoblastic lymphoma 30.1 TP53 TNFRSF8 CD7 CD4
24 severe combined immunodeficiency 30.1 IL2RA IL2 CD7 CD4 CCR6 BCL11B
25 chronic graft versus host disease 30.0 IL2RA CD4
26 combined t cell and b cell immunodeficiency 30.0 IL2 FOXP3 CD4 CCR6
27 intermediate uveitis 30.0 IL2RA IL2 CCR6 CCR4
28 chickenpox 29.9 IL2 CD4 CCR6
29 anogenital venereal wart 29.8 TP53 IL2 CD4
30 hypersplenism 29.8 IL2RA FOXP3 CD4
31 anemia, autoimmune hemolytic 29.8 IL2 FOXP3 CD4
32 pfeiffer syndrome 29.7 TNFRSF8 IL2 CD4 CCR6
33 lymphadenitis 29.7 IL2RA CD4 CCR6
34 acquired immunodeficiency syndrome 29.7 TP53 IL2RA IL2 CD4 CCR6
35 aplastic anemia 29.6 TP53 IL2RA IL2 FOXP3 CD4
36 sarcoidosis 1 29.4 IL2RA IL2 CD4 CCR6
37 viral infectious disease 29.3 IL2RA IL2 CD4 CCR6
38 listeriosis 29.3 IL2 CD4 CCR6
39 progressive multifocal leukoencephalopathy 29.3 IL2 CD4 CCR6
40 leukemia, acute myeloid 29.2 TP53 TNFRSF8 PMAIP1 IL2 CD7 CD4
41 leukemia, chronic lymphocytic 29.2 TXN TP53 TNFRSF8 PMAIP1 IL2RA IL2
42 allergic hypersensitivity disease 29.2 IL2 FOXP3 CD4 CCR6 CCR4
43 leprosy 3 29.2 IL2 FOXP3 CD4 CCR6
44 epidermodysplasia verruciformis 1 29.2 TP53 CD4 CCR6
45 lymphoma, non-hodgkin, familial 29.2 TP53 TNFRSF8 PMAIP1 IL2RA IL2 CD7
46 vitiligo-associated multiple autoimmune disease susceptibility 1 29.1 IL2 CD4 CCR6
47 human immunodeficiency virus infectious disease 29.1 IL2RA IL2 CD4 CCR6
48 bone inflammation disease 29.1 IL2 FOXP3 CD4 CCR6
49 sezary's disease 29.0 TNFRSF8 IL2RA IL2 FOXP3 CD7 CD4
50 skin disease 29.0 TNFRSF8 IL2 FOXP3 CD7 CD4 CCR6

Graphical network of the top 20 diseases related to Adult T-Cell Leukemia:



Diseases related to Adult T-Cell Leukemia

Symptoms & Phenotypes for Adult T-Cell Leukemia

MGI Mouse Phenotypes related to Adult T-Cell Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.93 BCL11B BCL2L1 CADM1 CD4 CD7 FOXP3
2 hematopoietic system MP:0005397 9.86 BCL11B BCL2L1 CADM1 CCR4 CCR6 CD4
3 immune system MP:0005387 9.53 BCL11B BCL2L1 CADM1 CCR4 CCR6 CD4

Drugs & Therapeutics for Adult T-Cell Leukemia

Drugs for Adult T-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4 Reverse Transcriptase Inhibitors Phase 4
5 Interferon-alpha Phase 4
6 Interferon alpha-2 Phase 4
7 interferons Phase 4
8 GABA Agents Phase 4
9 Antimanic Agents Phase 4
10 Anticonvulsants Phase 4
11
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
12 Orange Approved Phase 3
13
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
14
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
15
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
21
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
22
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
23
Dalteparin Approved Phase 3 9005-49-6
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 3 82419-36-1 4583
27
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
28
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
29
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
30
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
31
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
32
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
33
Piperacillin Approved Phase 3 66258-76-2 43672
34
Tazobactam Approved Phase 3 89786-04-9 123630
35
Vancomycin Approved Phase 3 1404-90-6 441141 14969
36
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
37
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
38
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
39
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
40
Daunorubicin Approved Phase 3 20830-81-3 30323
41
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
42
rituximab Approved Phase 3 174722-31-7 10201696
43
Melphalan Approved Phase 3 148-82-3 4053 460612
44
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
45
Pegaspargase Approved, Investigational Phase 3 130167-69-0
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
48
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
49
leucovorin Approved Phase 3 58-05-9 6006 143
50
Mercaptopurine Approved Phase 3 50-44-2 667490

Interventional clinical trials:

(show top 50) (show all 356)
# Name Status NCT ID Phase Drugs
1 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
5 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
8 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
9 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
10 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
11 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
12 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
14 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
15 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
16 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
17 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
18 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
19 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
20 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
21 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
22 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
23 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
24 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
25 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
26 A Phase III Study of Involved Field Radiation Therapy (IFRT) in Patients With Histologically Aggressive Non-Hodgkin's Lymphoma Following High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Completed NCT00031668 Phase 3
27 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
28 ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
29 Treatment of Acute Lymphoblastic Leukemia in Children Completed NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
30 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
31 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Recruiting NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
32 A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia Recruiting NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
33 A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008. Active, not recruiting NCT00707083 Phase 3 dexamethasone;mercaptopurine;methotrexate;vincristine sulfate
34 Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
35 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Unknown status NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
36 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
37 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
38 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
39 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
40 Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia Unknown status NCT00003885 Phase 2 arsenic trioxide
41 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
42 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
43 DFCI ALL Adult Consortium Protocol: Adult ALL Trial Unknown status NCT01005758 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide phosphate;hydrocortisone sodium succinate;imatinib mesylate;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;prednisone;vincristine sulfate
44 MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) Unknown status NCT00002531 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;teniposide;thioguanine;vincristine sulfate;vindesine
45 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
46 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2
47 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
48 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
49 Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed NCT01626664 Phase 2 Pralatrexate;gemcitabine plus oxaliplatin;DHAP
50 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease) Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)

Search NIH Clinical Center for Adult T-Cell Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Adult T-Cell Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Adult T-Cell Leukemia:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Adult T-Cell Leukemia:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: leukemia-lymphoma, adult t-cell

Genetic Tests for Adult T-Cell Leukemia

Anatomical Context for Adult T-Cell Leukemia

MalaCards organs/tissues related to Adult T-Cell Leukemia:

40
T Cells, Bone, Skin, B Cells, Bone Marrow, Liver, Breast

Publications for Adult T-Cell Leukemia

Articles related to Adult T-Cell Leukemia:

(show top 50) (show all 4615)
# Title Authors PMID Year
1
Production and characterization of an active single-chain variable fragment antibody recognizing CD25. 54 61
15978327 2005
2
Activation of interleukin-2 receptor alpha expression by extracellular HTLV-I Tax1 protein: a potential role in HTLV-I pathogenesis. 54 61
1501887 1992
3
Hypercalcemia and production of parathyroid hormone-like protein in adult T-cell leukemia-lymphoma. 54 61
1644163 1992
4
Rearrangement of human T cell receptor beta and gamma chain genes in adult T cell leukemia/lymphoma. 54 61
2160910 1990
5
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). 61
32024820 2020
6
Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States. 61
31769871 2020
7
Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area. 61
31721034 2020
8
Sensitive Photodynamic Detection of Adult T-cell Leukemia/Lymphoma and Specific Leukemic Cell Death Induced by Photodynamic Therapy: Current Status in Hematopoietic Malignancies. 61
32024297 2020
9
An Unusual Presentation of HTLV associated Adult T Cell Lymphoma/ Leukemia- an Eye that said it 'A (T) LL'. 61
32037902 2020
10
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells. 61
31765670 2020
11
Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors. 61
31592701 2020
12
Epigenetics evaluation of the oncogenic mechanisms of two closely related bovine and human deltaretroviruses: A system biology study. 61
31698053 2020
13
Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent. 61
32027454 2020
14
Updates in lymph node and skin pathology of adult T-cell leukemia/lymphoma, biomarkers, and beyond. 61
31889601 2020
15
Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. 61
31996318 2020
16
Mantle cell lymphoma mimicking adult T-cell leukemia. 61
32019688 2020
17
Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission. 61
32006150 2020
18
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. 61
31922287 2020
19
Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. 61
31934889 2020
20
Feed-forward Regulatory Loop Driven by IRF4 and NF-κB in Adult T-cell Leukemia/Lymphoma. 61
31972002 2020
21
Inefficient Tax-specific T-cell responses in mice after syngeneic transplantation with tax-transgenic mouse-derived adult T-cell leukemia cells. 61
32009059 2020
22
Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission. 61
31534195 2020
23
Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. 61
31961925 2020
24
A pilot study to establish human T-cell leukemia virus type 1 (HTLV-1) carrier model using common marmoset (Callithrix jacchus). 61
31930552 2020
25
HTLV-1 bZIP factor: the key viral gene for pathogenesis. 61
31915026 2020
26
Corrigendum to 'Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis' [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700]. 61
31610149 2020
27
Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review. 61
31978091 2020
28
Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma. 61
31840838 2020
29
Cutaneous lymphoma in Japan, 2012-2017: A nationwide study. 61
32033869 2020
30
Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient. 61
31930455 2020
31
Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab. 61
31004017 2019
32
Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma. 61
31041884 2019
33
Functional Analysis of Aberrantly Spliced Caspase8 Variants in Adult T-Cell Leukemia Cells. 61
31594868 2019
34
Dichotomy in Fatal Outcomes in a Large Cohort of People Living with HTLV-1 in São Paulo, Brazil. 61
31888093 2019
35
Orbital Adult T-Cell Leukemia/lymphoma With Skin Involvement Demonstrated on FDG PET/CT. 61
31524675 2019
36
Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma. 61
31104532 2019
37
Mouse model recapitulates the phenotypic heterogeneity of human adult T-cell leukemia/lymphoma in bone. 61
31871882 2019
38
CD4-/CD8+ adult T-cell leukemia/lymphoma with unusual morphology presenting as ascites and pleural effusion. 61
31820571 2019
39
High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for staging. 61
31204876 2019
40
Targeting RAD51 enhances chemosensitivity of adult T‑cell leukemia‑lymphoma cells by reducing DNA double‑strand break repair. 61
31638261 2019
41
High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor. 61
31614144 2019
42
CD4+ CADM1+ cell percentage predicts disease progression in HTLV-1 carriers and indolent adult T-cell leukemia/lymphoma. 61
31642546 2019
43
NF-κB and MicroRNA Deregulation Mediated by HTLV-1 Tax and HBZ. 61
31835460 2019
44
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for ATL with HTLV-1 Antibody-Positive Donors. 61
31821886 2019
45
Association of CD204+ macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT. 61
31487403 2019
46
Complete genome sequence of human T-cell lymphotropic type 1 from patients with different clinical profiles, including infective dermatitis. 61
31883457 2019
47
HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. 61
31648512 2019
48
HTLV-1 infection of myeloid cells: from transmission to immune alterations. 61
31870397 2019
49
Doxorubicin-associated takotsubo cardiomyopathy in a patient with adult T-cell leukemia/lymphoma. 61
31893081 2019
50
Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. 61
31704289 2019

Variations for Adult T-Cell Leukemia

ClinVar genetic disease variations for Adult T-Cell Leukemia:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NT5C2 NM_012229.4(NT5C2):c.1100G>A (p.Arg367Gln)SNV not provided 376349 rs1057519866 10:104852955-104852955 10:103093198-103093198
2 NT5C2 NM_012229.4(NT5C2):c.1075A>C (p.Lys359Gln)SNV not provided 376350 rs1057519867 10:104852980-104852980 10:103093223-103093223
3 NT5C2 NM_012229.4(NT5C2):c.1220A>C (p.Asp407Ala)SNV not provided 376351 rs1057519868 10:104850745-104850745 10:103090988-103090988

Expression for Adult T-Cell Leukemia

Search GEO for disease gene expression data for Adult T-Cell Leukemia.

Pathways for Adult T-Cell Leukemia

Pathways related to Adult T-Cell Leukemia according to KEGG:

36
# Name Kegg Source Accession
1 Human T-cell leukemia virus 1 infection hsa05166
2 Viral carcinogenesis hsa05203

Pathways related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 TP53 TNFRSF8 SPOCK3 PMAIP1 IL2RA IL2
2
Show member pathways
13.26 TP53 TNFRSF8 IL2RA IL2 CD4 CCR6
3 12.67 TP53 PMAIP1 IL2RA IL2 BCL2L1
4
Show member pathways
12.39 IL2RA IL2 FOXP3 CD4 BCL2L1
5
Show member pathways
12.28 TP53 IL2RA IL2 BCL2L1
6
Show member pathways
12.13 IL2RA IL2 CCR6 CCR4
7 12.06 TP53 IL2RA IL2 CD4 BCL2L1
8 11.68 TXN TNFRSF8 PDLIM2 IL2RA IL2 FOXP3
9
Show member pathways
11.58 IL2RA IL2 FOXP3
10 11.55 TP53 PMAIP1 BCL2L1
11
Show member pathways
11.38 IL2RA IL2 FOXP3 BCL2L1
12 11.36 TP53 IL2 BCL2L1
13 11.26 IL2RA IL2 CD7 CD4 CCR6
14 11.15 TP53 PMAIP1 BCL2L1
15 11.12 IL2RA IL2 FOXP3 CD4
16 10.99 IL2RA IL2 CD4
17 10.62 TP53 BCL2L1

GO Terms for Adult T-Cell Leukemia

Biological processes related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.95 TP53 TNFRSF8 PTHLH FOXP3 BCL11B
2 immune response GO:0006955 9.88 IL2RA IL2 CD7 CD4 CCR6 CCR4
3 cytokine-mediated signaling pathway GO:0019221 9.85 TP53 IL2RA IL2 CD4 BCL2L1
4 positive regulation of T cell proliferation GO:0042102 9.7 IL2RA IL2 CD4
5 T cell activation GO:0042110 9.69 FOXP3 CD7 CD4
6 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.67 TP53 PMAIP1 BCL2L1
7 response to radiation GO:0009314 9.65 TXN CCR4 BCL2L1
8 positive regulation of regulatory T cell differentiation GO:0045591 9.58 IL2 FOXP3
9 interleukin-2-mediated signaling pathway GO:0038110 9.57 IL2RA IL2
10 positive regulation of protein oligomerization GO:0032461 9.56 TP53 PMAIP1
11 negative regulation of T-helper 17 cell differentiation GO:2000320 9.54 IL2 FOXP3
12 T cell homeostasis GO:0043029 9.54 PMAIP1 IL2RA FOXP3
13 regulation of T cell homeostatic proliferation GO:0046013 9.43 IL2RA IL2
14 release of cytochrome c from mitochondria GO:0001836 9.43 TP53 PMAIP1 BCL2L1
15 regulation of regulatory T cell differentiation GO:0045589 9.33 IL2RA IL2 FOXP3
16 tolerance induction GO:0002507 9.32 FOXP3 CCR4
17 regulation of mitochondrial membrane permeability GO:0046902 9.13 TP53 PMAIP1 BCL2L1
18 negative regulation of lymphocyte proliferation GO:0050672 8.8 IL2RA IL2 FOXP3

Molecular functions related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 TXN TP53 TNFRSF8 SPOCK3 PTHLH PRDM16

Sources for Adult T-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....